Inactive Instrument

Alder BioPharmaceuticals, Inc.

US0143391052

Biotechnology & Medical Research

Alder BioPharmaceuticals, Inc. Announces the Retirement of Larry Benedict, Executive Vice President and Principal Accounting Officer, Effective May 3, 2019

April 12, 2019 at 05:01 pm EDT

On April 9, 2019, Larry Benedict, Executive Vice President and Principal Accounting Officer of Alder BioPharmaceuticals, Inc. announced his decision to retire on May 3, 2019.

Latest news about Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. Announces Board Changes	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Biotechnology Select Industry Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Global BMI Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P TMI Index	19-10-22	CI
H. Lundbeck A/S completed the acquisition of Alder BioPharmaceuticals, Inc..	19-10-21	CI
Alder BioPharmaceuticals, Inc. Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	19-10-10	CI
H Lundbeck : Lundbeck buys Alder in $2 billion migraine treatment move	19-09-16	RE
H. Lundbeck A/S signed a Letter of Intent to acquire Alder BioPharmaceuticals, Inc. for $1.5 billion.	19-09-15	CI
Transcript : Alder BioPharmaceuticals, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-10-2019 02:55 PM	19-09-10
Transcript : Alder BioPharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019	19-08-06
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-06	CI
Alder BioPharmaceuticals, Inc. Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention	19-07-11	CI
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting	19-07-08	CI
Transcript : Alder BioPharmaceuticals, Inc. - Analyst/Investor Day	19-06-26
Transcript : Alder BioPharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2019, May-22-2019 10:00 AM	19-05-22
Alder Biopharmaceuticals, Inc. Announces New Analysis of Patient-Report Outcomes Data from the Promise-2 Phase 3 Clinical Trial of Eptinezumab	19-05-08	CI
Alder BioPharmaceuticals, Inc. Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention	19-05-08	CI
Alder BioPharmaceuticals Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine Across Four Clinical Trials	19-05-06	CI
Transcript : Alder BioPharmaceuticals, Inc., Q1 2019 Earnings Call, May 02, 2019	19-05-02
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-02	CI
Alder Biopharmaceuticals, Inc. Announces Resignation of Deepika R. Pakianathan as Class II Director	19-04-30	CI
Certain Stock Options of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Restricted Stock Units of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Class A-1 Convertible Preferred Stock of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Alder Biopharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting	19-04-23	CI

Chart Alder BioPharmaceuticals, Inc.

Duration

Period

More charts

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.26%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-5.89%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs